Log In
BCIQ
Print this Print this
 

ombitasvir/paritaprevir/ritonavir/dasabuvir (Viekira XR)

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionOnce-daily, extended-release, co-formulation of ombitasvir, an HCV NS5A protein inhibitor; paritaprevir, an HCV NS3/4A protease inhibitor; ritonavir, an HIV protease inhibitor; and dasabuvir, a non-nucleoside HCV NS5B polymerase inhibitor
Molecular Target HCV NS3/4A protease complex ; HCV NS5A protein
Mechanism of ActionHIV protease inhibitor; HCV non-structural protein 5A inhibitor; HCV non-structural protein 5B inhibitor; HCV NS3 protease inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentApproved
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection with and without compensated cirrhosis
Regulatory Designation
PartnerEnanta Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today